Drug class
Topical androgen receptor antagonist; steroidal antiandrogen
Mechanism of action
Competitively antagonises androgen receptors in skin, blocking local androgen signalling in sebaceous glands and hair follicles. It reduces androgen-mediated sebum production and inflammatory signalling without relying on systemic androgen suppression.
General use cases
- Topical treatment of acne vulgaris in patients aged 12 years and older under the US WINLEVI indication
- Clascoterone 5% solution for androgenetic alopecia has been studied; do not present hair-loss treatment as an approved indication unless a current jurisdiction-specific authorisation is confirmed
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
